Liminatus Pharma, Inc. Class A Common Stock
Here’s whether Liminatus Pharma, Inc. Class A Common Stock (LIMN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-9.89% over 10 days); weak 1-year return of -96.6%; 3-month momentum negative (-22.2%); rising volume on a downtrend (distribution, 1.27x avg). Currently 97.1% off its 52-week high. Score: -4/7.
LIMN is trading below its 200-day MA ($0.46) — a key warning sign the longer-term trend is under pressure. An RSI of 65.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -96.6% compares to +20.4% for SPY (trailed the market by 117.0%). The current 97.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.